Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer drug PM54 enters first human tests

NCT ID NCT05841563

Recruiting now Disease control Sponsor: PharmaMar Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial is testing an experimental drug called PM54 in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose by watching for side effects, and second, checking if the drug can shrink tumors. About 125 adults will take part, and the drug is given through an IV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PM54 (an experimental drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 125 participants, so the main goal is safety, not effectiveness. Many experimental drugs fail at this stage, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • HM Universitario Sanchinarro

    RECRUITING

    Madrid, M, 28050, Spain

    Contact

  • Institut Jules Bordet

    RECRUITING

    Anderlecht, 1070, Belgium

    Contact

  • South Texas Accelerated Research Therapeutics

    RECRUITING

    San Antonio, Texas, 78229-3307, United States

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.